NCT01645423已完成1 期
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fed Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 77
- 试验地点
- 1
- 主要终点
- Area under curve (AUC)
研究概览
简要总结
The purpose of this study is to compare and evaluate the single-dose oral bioavailability and to monitor the safety of subjects.
详细描述
An open label, balanced, randomized, two-treatment, two-period, two-way crossover oral bioequivalence' study of Atorvastatin Calcium 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals in healthy adult, human subjects under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects aged between 18 and 45 years (both inclusive).
- •Subjects' weight within normal range according to normal values for Body Mass Index (1 8.5 to 24.9 kg/m2) with minimum of 50 kg weight.
- •Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations (Annexure IIIa) within the clinically acceptable reference range (Annexure IIIb).
- •Subjects having normal 12-lead electrocardiogram (ECG).
- •Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6 months prior to the dosing of Period 0
- •Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- •Subjects having negative alcohol breath test.
- •Subjects willing to adhere to the protocol requirements and to provide written informed consent.
排除标准
- •Subjects will be excluded from the study, if they meet any of the following criteria:
- •Hypersensitivity to Atorvastatin or related class of drugs.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
- •Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
- •History or presence of significant alcoholism or drug abuse in the past one year.
- •History or presence of significant smoking (more than 10 cigarettes or beedi's/day).
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric andlor duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •History or presence of cancer.
- •Difficulty with donating blood.
- •Difficulty in swallowing solids like tablets or capsules.
- •Use of any prescribed or OTC medication during last two weeks prior to dosing in period 0
- •Major illness during 3 months before screening.
- •Participation in a drug research study within past 3 months.
- •Donation of blood in the past 3 months before screening.
- •Consumption of grapefruit juice, xanthine-containing products, tobacco containing products or alcohol for within 48 hours prior to dosing.
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
研究组 & 干预措施
Atorvastatin Calcium Tablets, 80 mg
Experimental
Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
干预措施: Atorvastatin Calcium Tablets, 80 mg (Drug)
Lipitor 80 mg Tablets
Active Comparator
Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
干预措施: Atorvastatin Calcium Tablets, 80 mg (Drug)
结局指标
主要结局
Area under curve (AUC)
时间窗: Pre-dose at 0.00 hour and post-dose at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50 1.75, 2.00, 2.25,2.50, 2.75, 3.00, 3.33, 3.67,4.00,4.50, 5.00,6.00, 8.00, 10.00, 12.00, 16.00,24.00, 36.00, 48.00 and 72.00 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting ConditionsHealthyNCT01645449Dr. Reddy's Laboratories Limited77
已完成
1 期
Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting ConditionsHealthyNCT01164787Dr. Reddy's Laboratories Limited52
已完成
1 期
Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed ConditionsHealthyNCT01164800Dr. Reddy's Laboratories Limited52
已完成
1 期
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.BioequivalenceDiabetes Mellitus, Type 2NCT06124573Galenicum Health48
已完成
1 期
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.BioequivalenceDiabetes Mellitus, Type 2NCT06124547Galenicum Health48